Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Investor Presentation (February 2015)
50 slides from Immutep's investor presentation, Feb 27, 2015
Slide 1: Detailed Backgrounder Presentation
Exhibit 99.2 PRIMA Nasdaq: Detailed 27 Presentation Marc www.primabiomed.com.au February Voigt BIOMED PBMD, Backgrounder (CEO) 2015ASX:PRR and Stuart Roberts (Global Head of IR)
Slide 2: Immuno-Oncology: A cancer treatment revolution
2PRIMA Nasdaq: Immuno-Oncology: Our Beneficiaries: 27 February LAG-3 BIOMED PBMD, programs: 2015 Patients…and ASX:PRR Detailed A cancer An important Backgrounder our treatment shareholders partRevolution of Presentation the Revolution Marc Voigt (CEO) and Stuart Roberts (Global Head of IR) www.prima
Slide 3: Notice: Forward Looking Statements
3Notice: presentation announcements The information. or expectations from plans, forecast 27 Marc PRIMA www.primabiomed.com.au Nasdaq: reliability February purpose views assumptions Voigt expectations Forward BIOMED by PBMD, expressed Prima (CEO) 2015 aid of andthe made only ASX:PRR Looking beliefs
Slide 4: Focus on LAG-3 and ceasing CVac development
-4Prima 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Between InFebruary late 2015 Voigt BioMed 2014 BIOMED PBMD, we 2001 (CEO) 2015 will we isand ASX:PRR acquired changing concentrate Detailed and 2014 Stuart we Paris-based Backgrounder developed Roberts on LAG-3 (Global Immutep arelated Presentatio
Slide 5: Prima BioMed: next big immuno-oncology company
5PA -next 27 Marc PRIMA www.primabiomed.com.au Nasdaq: rima The February cancer global company big Voigt Immutep BioMed BIOMED immuno-oncology PBMD, company drug (CEO) 2015 with today portfolio development ASX:PRR Detailed aand dominant with Stuart has talent Backgrounder target, multiple company Ro
Slide 6: In this presentation
6InSlide –LAG-3 Why 27 Marc PRIMA www.primabiomed.com.au Nasdaq: this February we invest Voigt presentation 7–BIOMED PBMD, are The (CEO) in ceasing 2015 Next Prima? ASX:PRR Detailed and Big … clinical –Stuart Immune Slide Backgrounder development Roberts 43 Checkpoint (Global Presentation of Target
Slide 7: LAG-3: The Next Big Immune Checkpoint Target
7LAG-3: CHECKPOINT 27 Backgrounder Marc (Global PRIMA www.primabiomed.com.au Nasdaq: February Voigt Head BIOMED THE PBMD, (CEO) 2015 NEXT of Presentation TARGET IR) ASX:PRR Detailed and BIG Stuart IMMUNE … Roberts
Slide 8: The Immuno-Oncology Revolution
-8TYervoy® 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Very Keytruda® Opdivo® heFebruary Immuno-Oncology Voigt good BIOMED PBMD, (ipilimumab) (nivolumab) (CEO) data 2015 (pembrolizumab), ASX:PRR (with Detailed and the Stuart Revolution from from right Backgrounder BMS, Roberts BMS, from patients) i
Slide 9: Immuno-Oncology market forecast
9Immuno-Oncology 2013 -2025 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Oncology Immuno-Oncology Success February (source: (Citi Voigt BIOMED PBMD, stories Research, (CEO) is2015 world‘s IMS) ASX:PRR like Detailed and will May –Rituxan® largest potentially Stuart create 2013) Backgrounder drug Robe
Slide 10: Pharma companies positioning in immuno-oncology
Pharma -10 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Roche/immatics, BMS Boehringer February Voigt / companies BIOMED Five PBMD, (CEO) 2015 Ingelheim Prime, ASX:PRR Detailed November and are March now Stuart / CureVac, Backgrounder 2014 positioning Roberts 2013– September $20m – Collaboration (Gl
Slide 11: Pharma companies positioning in immuno-oncology
Pharma -11 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Celgene Pfizer February Voigt /companies BIOMED PBMD, Merck / Sutro, (CEO) 2015KGaA, ASX:PRR October Detailed and are now Stuart November 2014 Backgrounder positioning Roberts – $95m 2014 (Global toupfront –Presentation benefit… US$550m Head (i
Slide 12: Immuno-Oncology development trends
There 12 -oncology 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Trend WeFebruary benefit Voigt are 1BIOMED 2PBMD, –drugs targets two Development Combinations (CEO) 2015 from basic (eg ASX:PRR (eg both Detailed and Lilly trends Various Stuart trends trialling of of to Backgrounder new existing PD-L1
Slide 13: Big Six immuno-oncology targets
13 February This OX40 CTLA-4 PD-1/PD-L1 LAG-3 27 Marc PRIMA www.primabiomed.com.au Nasdaq: isVoigt where PRR’s TIM-3 isBIOMED PBMD, one (CEO) 2015 most of target GITR ASX:PRR the Detailed and immuno-oncology ‘Big Stuart Six’ Backgrounder Roberts immuno-oncology (Global action Presentation has Head b
Slide 14: LAG-3 in anti-tumor immunity
LAG-3 14 IL-6, Tumor B7-H3 DC/M Maturation/ PD-L TGF CD40 Effective MDSC IL10, CD137 PD-1 T TIM3 Tumor- Source: 27 Marc PRIMA www.primabiomed.com.au Nasdaq: reg February IL-10, Voigt LAG-3 cell TGF 1/2 PD-L IDO B7-H4 involved OX40 specific Pardoll BIOMED PBMD, anti-tumor Arginase (CEO) activation VE
Slide 15: What is LAG-3?
What 15 -Class 27 Marc PRIMA www.primabiomed.com.au LAG-3 Since OnFebruary T dendritic Voigt is IIcells, LAG-3 LAG-3? co-caps BIOMED (CD223) is a(CEO) 2015 LAG-3 ligand cells iswith widely Detailed -and LAG-3 for “Lymphocyte isCD3/TCR an Stuart MHC expressed inhibitory Backgrounder is Roberts an cla
Slide 16: LAG-3 and PD-1 dual targeting
LAG-3 -16 27 Marc PRIMA www.primabiomed.com.au Dual LAG-3 February Voigt targeting isBIOMED ispromising works seems expressed (CEO) 2015 to by ofDetailed be LAG-3 and direct as vital onStuart a multiple drug effects for and Backgrounder Roberts Treg target PD-1 ontumour-infiltrating functioning CD8+
Slide 17: We lead the LAG-3 field
We -17 warrants) 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Triebel Immutep Professor February lead Voigt BIOMED the PBMD, et.was Triebel Frédéric (CEO) al., LAG-3 2015 formed asASX:PRR Detailed part and isfield Triebel now of Stuart in… aParis our Backgrounder collaboration discovered Roberts Chi
Slide 18: LAG-3 interest has heightened
LAG-3 -18 27 Marc PRIMA www.primabiomed.com.au Nasdaq: After The Immutep Initial …but February Voigt Immuno-Oncology >15 since has Phase BIOMED PBMD, was years lagged (CEO) 2015 2011 IIadata ASX:PRR small, work Detailed global PD-1 andwasn’t Stuart by venture-backed and Revolution search Triebel Bac
Slide 19: Big Pharma players in LAG-3
Pharma -19 27 Marc PRIMA www.primabiomed.com.au Nasdaq: This Bristol-Myers BMS Novartis PRR February Voigt is expects isis BIOMED distinct PBMD, developing already licensed (CEO) 2015 other Squibb from ASX:PRR Detailed looking and LAG-3 Big LAG-3 PRR’s Stuart (BMS) Pharma at antibodies Backgrounder
Slide 20: We own three main LAG-3 technologies
We -20 27 Marc PRIMA www.primabiomed.com.au Nasdaq: IMP321 IMP731 IMP701 February own Voigt BIOMED PBMD, three – (CEO) soluble LAG-3 2015 main ASX:PRR Detailed and depleting antagonist LAG-3 Stuart Backgrounder protein technologies antibody Roberts antibody for(Global cancer for for … Presentation a
Slide 21: Programs reaching the clinic
… February 21 Phase Our IMP321 GSK2831781 PHARM IMP701 27 Marc PRIMA www.primabiomed.com.au Nasdaq: two partners Voigt I of Phase BIOMED PBMD, Cancer which (CEO) 2015 Autoimmune IIaNOVARTIS EDDING have ASX:PRR Phase Detailed andreached Stuart IIb Backgrounder Phase diseases Roberts the III clinic GS
Slide 22: Partners ranked among world's largest pharma
…Ranked 22 One EDDING IMP321 GSK IMP731 World’s *NOVARTIS IMP701 PharmaExec50 27 Marc PRIMA www.primabiomed.com.au Nasdaq: allof February World’s Voigt ofthe BIOMED largest PBMD, PHARM pharma* which by growing fastest- (CEO) 2015 pharma* Rx 6th have list, sales ASX:PRR largest pharmas Detailed and s
Slide 23: Our basic strategy
Our -23 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Hold Benefit February basic Voigt upside BIOMED PBMD, from strategy (CEO) 2015 in antibodies markets ASX:PRR Detailed for andLAG-3 Stuart outside toBackgrounder LAG-3 Roberts China through (Global forPresentation soluble commercial HeadLAG-3 of IR
Slide 24: IMP321 - T cell adjuvant
IMP321 24 -cell adjuvant 27 Marc PRIMA www.primabiomed.com.au Nasdaq: A We Induces Phase February soluble expansion also Voigt IIa BIOMED PBMD, is for activation believe soluble data dimeric (CEO) cancer 2015 follows inASX:PRR that Detailed metastatic LAG-3 and recombinant vaccines ofIMP321 dendriti
Slide 25: APC-based mechanism of action of IMP321
APC-based -25 PD-1 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Antibodies This Soluble February Voigt inhibition suggests BIOMED PBMD, LAG-3 (CEO) Mechanism 2015 to LAG-3 that ASX:PRR can Detailed and soluble increase upregulate Stuart of Action Backgrounder LAG-3 Roberts activation -IMP321 T-cell
Slide 26: IMP321 in metastatic renal cell carcinoma
267Sustained in IMP321 -CD8 27 Marc PRIMA www.primabiomed.com.au Nasdaq: NmRCC February of =TVoigt 21, 8 cells evaluable BIOMED PBMD, showed as open (Clin aCD8 (CEO) in 2015 monotherapy label all Cancer ASX:PRR promise T-cell patients Detailed and study Stuart activation, Res. atdosed in atBackgroun
Slide 27: IMP321 plus paclitaxel in breast cancer
IMP321 Response IMP321+paclitaxel 0% 10% 20% 30% 40% 50% 60% another -paclitaxel, 27 Marc PRIMA www.primabiomed.com.au Nasdaq: NFebruary 50% Expected Result = Voigt 30, response 40% BIOMED over PBMD, doubled open rate nresponse (CEO) 2015 =(Journal historic (RECIST 273, label rate, ASX:PRR response
Slide 28: IMP321 Phase IIb plans
IMP321 -28 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Drug Randomised, Pilot February Voigt Phase has BIOMED PBMD, goes been (CEO) 2015 Iback study double-blind manufactured ASX:PRR Detailed and tointhe an Stuart clinic immuno-oncology Backgrounder placebo-controlled Roberts by this WuXi-AppTec ye
Slide 29: IMP321 partnered with Eddingpharm in China
IMP321 -29 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Immutep Eddingpharm China‘s February Voigt BIOMED PBMD, isdrug licensed partnered (CEO) 2015 market isASX:PRR aDetailed and leading rights with isStuart one for Eddingpharm Backgrounder specialty of China Roberts the world‘s and pharmaceutical
Slide 30: IMP731 licensed to GSK
IMP731 GSK -30 (~A$118m) 27 Marc PRIMA www.primabiomed.com.au Dec. GSK2831781 February Voigt 2010: BIOMED for (CEO) autoimmune 2015 GlaxoSmithKline is currently Detailed and Stuart diseases Backgrounder in Roberts first licensed time(Global in from Presentation human Immutep Head clinical of IR) rig
Slide 31: IMP731 preclinical data and GSK Phase I
IMP731 -31 Exp GSK’s T 27 Marc PRIMA www.primabiomed.com.au A In cells February tuberculin-induced January Immunol. Voigt investigational that BIOMED forare (CEO) autoimmune 2015, 2015 2011 auto-reactive Detailed Prima and May; product DTH Stuart announced diseases 164(2): Backgrounder model inRober
Slide 32: IMP701 partnered with Novartis
IMP701 NOVARTIS -32 27 Marc PRIMA www.primabiomed.com.au Nasdaq: IMP701 2012: Feb. February Voigt 2014: US BIOMED PBMD, isispartnered biotech (CEO) an 2015 Novartis anti-LAG-3 ASX:PRR Detailed and CoStim with bought Stuart Novartis Backgrounder licensed antibody CoStim RobertsLAG-3 which for (Global
Slide 33: Our intellectual property
Intellectual 33 -WO/2009/044273 27 Marc PRIMA www.primabiomed.com.au Our Claims Specifically Patents February Voigt LAG-3 BIOMED cover covering (CEO) property 2015 intellectual the LAG-3 gene, Detailed IMP321+chemo and and WO/2008/132601) protein Stuart proteins property Backgrounder Roberts and and
Slide 34: Why we are ceasing clinical development of our cancer vaccine
WHY 34 27 Cvac Backgrounder Marc (Global PRIMA www.primabiomed.com.au Nasdaq: February Voigt WEHead BIOMED PBMD, ARE (CEO) 2015 of Presentation CEASING IR) ASX:PRR Detailed and Stuart CLINICAL Roberts DEVELOPMENT OF OUR CANCER VACCINE
Slide 35: CVac: CAN-003 Phase II study
CVac: 35 CVac MUC1 Oxidised Phase 27 Marc PRIMA www.primabiomed.com.au Nasdaq: February Voigt isII Cancer isex BIOMED CAN-003 PBMD, mannan cell vivo (CEO) 2015 surface vaccine dendritic ASX:PRR as Detailed and study adjuvant protein Stuart in cell Backgrounder ovarian overexpressed Roberts priming i
Slide 36: Review of CVac clinical development program
We *-36 27 Marc PRIMA www.primabiomed.com.au We Our See February have indicated Voigt general AGM BIOMED been (CEO) presentation, 2015 priority reviewing thatIntroductory and wefor intended Stuart CVac CVac 14 November Roberts since Corporate in tolate “review October (Global 2014 2014, Presentation
Slide 37: CVac: CAN-003 overall survival
CVac: 37 Months CVac 24 26 28 30 32 34 36 -38 p=0.07) 27 Marc PRIMA www.primabiomed.com.au Nasdaq: Thesis: To Position: Overall February come: Voigt has Standard Our Overall BIOMED PBMD, CVac survival, shown Maintenance basic CAN-003 (CEO) 2015 will ofSurvival thesis ASX:PRR >10 care Detailed CAN-00
Slide 38: However, we are ceasing CVac clinical development
However… -38 27 Marc PRIMA www.primabiomed.com.au As Despite For February aPrima Voigt small consequence BIOMED the(CEO) in biotech 2015 promising 2015, Introductory and we company theStuart are nature lower ceasing Roberts we cost, of Corporate CVac, have recruitment higher (Global toand focus Pres
Slide 39: CVac partnering and monetisation opportunities
We -39 27 Marc PRIMA www.primabiomed.com.au The We PRR’s CVac February continue remain believe Voigt CAN-003 has BIOMED efficient Orphan (CEO) 2015 partnered to thatbenefit final manufacturing partnering Introductory and Drug Overall with from Stuart status Neopharm opportunities CVac Survival Rober
Slide 40: Dendreon Provenge revenue and financial difficulty
Inun-10 (even 0JQuarterly 10 20 30 40 50 60 70 80 90 Dec-14 Sep-14 Jun-14 Mar-14 Dec-13 Sep-13 Jun-13 Mar-13 Dec-12 Sep-12 Jun-12 Mar-12 Dec-11 Sep-11 Jun-11 Mar-11 Dec-10 -Sep-10 27 Marc PRIMA www.primabiomed.com.au Provenge® Nov. Feb. the February Voigt though future, 2014. 2014: BIOMED Provenge®
Slide 41: Why cease CVac development: lower cost, more upside
So -41 27 Marc PRIMA www.primabiomed.com.au As WeFebruary why noted will believe, Voigt are BIOMED lower seek above, (CEO) we 2015 into are our the retain cancer Introductory ceasing and light costStuart upside base of vaccines CVac recent significantly, Roberts through Corporate clinical are launch
Slide 42: Going Forward
GOING 42 27 Past Future Marc PRIMA www.primabiomed.com.au Nasdaq: February Voigt BIOMED FORWARD PBMD, (CEO) 2015ASX:PRR Introductory and …Stuart Roberts Corporate (Global Presentation Head of IR)
Slide 43: Why Invest in Prima?
WHY 43 27 Backgrounder Marc (Global PRIMA www.primabiomed.com.au Nasdaq: February Voigt INVEST Head BIOMED PBMD, (CEO) 2015 of Presentation IN IR) ASX:PRR Detailed and PRIMA? Stuart Roberts
Slide 44: Five important reasons to invest
Five -44 27 Marc PRIMA www.primabiomed.com.au Depth: Important Superior Partnerships: Leadership: February reasons Voigt BIOMED Change technology: (CEO) market 2015 to Strong GSK, invest from Detailed and space. board Novartis single-asset With Stuart Immuno-oncology and Backgrounder LAG-3, Roberts
Slide 45: Market capitalisation versus immuno-oncology peers
45edian peer USDm 0M 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 PRR Juno Kite Celldex Ziopharm NewLink Bavarian MacroGenics Five Bellicum Innate Northwest Immune Lion Agenus Stemline Peregrime Galena Argos Advaxis Coronado Scancell Mologen NeoStem Affirmed Galectin Trillium Cell-Sci O
Slide 46: Directors and senior management
We -46 Lucy Pete 27 Marc PRIMA www.primabiomed.com.au Directors: Senior February are Meyers Meyers, Turnbull Voigt, Voigt aBIOMED management: global (CEO) Lucy Berlin 2015 (ex Philadelphia AO, company Deutsche Turnbull Detailed and Sydney Marc Stuart Bank, AO Backgrounder Voigt Roberts (Chairman), n
Slide 47: Coming up in 2015
Coming -47 27 Marc PRIMA www.primabiomed.com.au Start Continued R&D CAN-003 Ongoing: February Voigt of for BIOMED up immuno-combination Phase new Business in (CEO) final expansion 2015 2015 products IIIb Overall for Detailed and with …IMP701 development of Stuart IMP321 Survival intellectual Backgro
Slide 48: Cash position and burn rate
Cash 48 -(A$13.2m) 27 PRIMA Nasdaq: A$2.2m Year 17February Jan. Dec. position 2015: toBIOMED PBMD, Dec. 2014: grant upfront, US$0.64m 2015 2014: support Immutep ASX:PRR Detailed US$2.7m Burn ($A0.78m) intransaction rate year Backgrounder (A$3.3m) ~toUS$1.0m Dec. Australian settled 2014. retentions P
Slide 49: Prima BioMed share data
Prima -49 27 Marc PRIMA www.primabiomed.com.au Nasdaq: ADRs Turnover: Current 12 Listed Unlisted ISIN: Share Shares Registered Substantial February month Voigt BioMed US745154B2034 ratio outstanding options BIOMED on available PBMD, market share options: range: ASX, (CEO) issue shareholders 2015 for
Slide 50: Thank you
PRIMA 50 Thank Stuart +61 stuart.roberts@primabiomed.com.au Professor Merci Marc Danke frederic.triebel@primabiomed.com.au 27 marc.voigt@primabiomed.com.au Detailed Nasdaq: February (0) Voigt, Roberts, you 447 BIOMED PBMD, Backgrounder Frédéric 247 CEO 2015 Global 909 ASX:PRR Triebel, Head Presentat